Feature|Podcasts|September 23, 2024
A Different Approach to Dermatology Care
Author(s)Miranda Schmalfuhs
Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, discusses their approach to orphan drug development, challenges and opportunities adapting to the US market, and more.
Advertisement
Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, discusses:
- How they're positioning the company to capitalize on the unmet needs in other specific therapeutic areas
- Strategies to ensure long-term success in these spaces
- Patient centric initiatives they've implemented to ensure the patient voice is integrated into drug development and commercialization processes
- Their approach to orphan drug development
- Challenges and opportunities adapting to the US market
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Elicio Therapeutics’ Shares Drop Following Announcement of Phase II Trial Results
2
Pharma Roundup: FDA Approves Truqap Plus Abiraterone and Prednisone, FDA Approves Keytruda and Keytruda Qlex Each in Combination with Welireg
3
Partnering in Non-Opioids: Q&A with Dr. Edward Littler and Dave Watson
4
Pharmaceutical Executive Daily: FDA Approves Two Indications of Keytruda in Combination with Welireg
5